|[May 14, 2014]
Avedro Welcomes Robert J. Palmisano to its Board of Directors
WALTHAM, Mass. --(Business Wire)--
Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical
company announces today that Robert J. Palmisano is joining its Board of
Directors. Mr. Palmisano is the current President & CEO of Wright
Medical Group, Inc. (NASDAQ: WMGI).
Mr. Palmisano has significant experience leading publicly-traded medical
device companies, most recently serving as President & CEO of ev3, Inc.,
a global endovascular device company, from April 2008 to July 2010 when
it was acquired by Covidien plc. Prior to ev3, Mr. Palmisano was an
instrumental leader in the ophthalmic medical device industry serving as
President & CEO of IntraLase Corp. from 2003 to 2007, when it was
acquired by AMO and serving as President & CEO of Summit Technology,
Inc. from 1997 to 2000 when it was acquired by Alcon, Inc. Earlier in
his career, he served in various executive positions at Bausch & Lomb
Incorporatd. During the past five years, Mr. Palmisano served on the
Board of Directors of ev3, Inc., Osteotech, Inc., Abbott Medical
Options, Inc., and Bausch & Lomb. Mr. Palmisano holds a B.A. degree in
Political Science from Providence College and currently serves on its
Board of Trustees.
"I have been excited about the potential of cross-linking technology
since my days with IntraLase. I am thrilled to join David Muller and the
Avedro team to do whatever I can to help bring this technology to the
market," Palmisano stated.
David Muller, PhD, CEO of Avedro states, "After my departure from Summit
Technology, Bob did an outstanding job in providing strategic guidance
to the company, thus positioning it for growth and ultimately to be
acquired. I am now looking forward to working with him on building the
future of Avedro and look forward to a very successful outcome."
Avedro is a privately held medical device and pharmaceutical company
advancing the science and technology of corneal cross-linking and
refractive correction. Avedro's products include capital equipment and
related single dose pharmaceuticals.
Avedro distributes its products in 62 countries through 33 ophthalmic
distributors with 115 sales and service representatives. Avedro products
that have received CE Mark include: the KXL® System for performing Lasik
Xtra® and Accelerated Cross-Linking, the KXL II™ System for performing
PiXL™, and the Avedro family of proprietary single dose pharmaceutical
Avedro's KXL System and single dose pharmaceutical products are
currently being used in three Phase III US clinical trials involving
over 100 US clinical sites. Avedro products are not for sale in the US.
[ Back To TMCnet.com's Homepage ]